User login
Epidemiology was the word of the day in a sampling of posters presented at the annual meeting of the American College of Rheumatology. Below are three posters that received a lot of attention at this year's meeting. The report on heart failure risk in rheumatoid arthritis was one of this year's blue ribbon–winning posters.
RA Severity Predicts Heart Failure
The risk for new-onset heart failure in patients with RA is greatest in patients with the most severe disease, Dr. Soko Setoguchi of Brigham and Women's Hospital in Boston and her associates reported. The research involves 8,483 patients whose RA was diagnosed by a rheumatologist and who were enrolled in the CORRONA (Consortium of Rheumatology Researchers of North America) registry. Patients were followed from the time of registry enrollment until Dec. 15, 2006, or death, whichever happened sooner. Patients' mean age was 59 years, 75% were female, 93% were white, 15% were current smokers, and their mean body mass index was 29 kg/m
Women's RA Risk Is Twice Men's
The lifetime risk for RA has remained “remarkably stable” during 1945-1995, according to Cynthia S. Crowson and her associates from the Mayo Clinic in Olmsted, Minn. For men, the lifetime risk is 1.8%; for women, it ranges from 3.4% to 3.7%. This stability occurred despite a gradual decrease in the incidence of RA from 1955 to the mid-1980s. More recently, women are experiencing an increased incidence, whereas that of men remains steady. The investigators used participants in the population-based incident cohort of Olmsted County who fulfilled the 1987 ACR criteria for RA between 1995 and 2005. These findings come from Poisson regression analyses performed to calculate the observed incidence rate in each sex. Calling the lifetime risk “significant” and women's higher lifetime risk “substantial,” the investigators noted an additional worry in their poster: The lifetime risk may be even higher in some subgroups with high-risk genotypes. This research was funded by the National Institutes of Health.
Uveitis Incidence Established in AS
Noninfectious uveitis is more than 20 times more common in patients with ankylosing spondylitis than in the general population, judging from findings presented by Shelagh M. Szabo of Oxford Outcomes in Vancouver, B.C., and colleagues. Using longitudinal physician billing data from Quebec province, the investigators calculated that 7,663 people were diagnosed with AS between 1998 and 2006 (the AS 1 group); another 3,006 people were diagnosed with AS during that time period and were seen for a related visit at least once during the next year (AS 2). The AS 1 group was designed to maximize sensitivity and the AS 2 group to maximize specificity. The AS 1 patients may have had milder disease. The investigators used a 1% random sample of unaffected individuals from Quebec (the population of which was 7.6 million in 2006) as the control group. The crude 10-year incidence of noninfectious uveitis in the AS 1 patients was 368 cases per 10,000 persons; for the AS 2 group, it was 482 cases per 10,000 persons; in the control group, the incidence was 21 cases per 10,000 persons. The standardized incidence ratio (SIR) for uveitis development during the study period was 18.04 for those in AS 1 vs. the controls. The SIR was 23.88 for those in the AS 2 group vs. controls. Age played a significant factor in incidence, with those in the 20- to 39-year-old age group having the largest risk. In the AS 1 group, the uveitis incidence was 53 cases per 1,000 persons in those aged 20-39 years vs. 33 per 1,000 for those aged 40-59 years, and 8 per 1,000 for those aged 60 years or older. In the AS 2 group, the uveitis incidence was 69 per 1,000 persons in those aged 20-39 years vs. 40 per 1,000 persons for those aged 40-59 years, and 13 per 1,000 for those aged 60 years or older. Several of the researchers were employed by Abbott Laboratories.
Epidemiology was the word of the day in a sampling of posters presented at the annual meeting of the American College of Rheumatology. Below are three posters that received a lot of attention at this year's meeting. The report on heart failure risk in rheumatoid arthritis was one of this year's blue ribbon–winning posters.
RA Severity Predicts Heart Failure
The risk for new-onset heart failure in patients with RA is greatest in patients with the most severe disease, Dr. Soko Setoguchi of Brigham and Women's Hospital in Boston and her associates reported. The research involves 8,483 patients whose RA was diagnosed by a rheumatologist and who were enrolled in the CORRONA (Consortium of Rheumatology Researchers of North America) registry. Patients were followed from the time of registry enrollment until Dec. 15, 2006, or death, whichever happened sooner. Patients' mean age was 59 years, 75% were female, 93% were white, 15% were current smokers, and their mean body mass index was 29 kg/m
Women's RA Risk Is Twice Men's
The lifetime risk for RA has remained “remarkably stable” during 1945-1995, according to Cynthia S. Crowson and her associates from the Mayo Clinic in Olmsted, Minn. For men, the lifetime risk is 1.8%; for women, it ranges from 3.4% to 3.7%. This stability occurred despite a gradual decrease in the incidence of RA from 1955 to the mid-1980s. More recently, women are experiencing an increased incidence, whereas that of men remains steady. The investigators used participants in the population-based incident cohort of Olmsted County who fulfilled the 1987 ACR criteria for RA between 1995 and 2005. These findings come from Poisson regression analyses performed to calculate the observed incidence rate in each sex. Calling the lifetime risk “significant” and women's higher lifetime risk “substantial,” the investigators noted an additional worry in their poster: The lifetime risk may be even higher in some subgroups with high-risk genotypes. This research was funded by the National Institutes of Health.
Uveitis Incidence Established in AS
Noninfectious uveitis is more than 20 times more common in patients with ankylosing spondylitis than in the general population, judging from findings presented by Shelagh M. Szabo of Oxford Outcomes in Vancouver, B.C., and colleagues. Using longitudinal physician billing data from Quebec province, the investigators calculated that 7,663 people were diagnosed with AS between 1998 and 2006 (the AS 1 group); another 3,006 people were diagnosed with AS during that time period and were seen for a related visit at least once during the next year (AS 2). The AS 1 group was designed to maximize sensitivity and the AS 2 group to maximize specificity. The AS 1 patients may have had milder disease. The investigators used a 1% random sample of unaffected individuals from Quebec (the population of which was 7.6 million in 2006) as the control group. The crude 10-year incidence of noninfectious uveitis in the AS 1 patients was 368 cases per 10,000 persons; for the AS 2 group, it was 482 cases per 10,000 persons; in the control group, the incidence was 21 cases per 10,000 persons. The standardized incidence ratio (SIR) for uveitis development during the study period was 18.04 for those in AS 1 vs. the controls. The SIR was 23.88 for those in the AS 2 group vs. controls. Age played a significant factor in incidence, with those in the 20- to 39-year-old age group having the largest risk. In the AS 1 group, the uveitis incidence was 53 cases per 1,000 persons in those aged 20-39 years vs. 33 per 1,000 for those aged 40-59 years, and 8 per 1,000 for those aged 60 years or older. In the AS 2 group, the uveitis incidence was 69 per 1,000 persons in those aged 20-39 years vs. 40 per 1,000 persons for those aged 40-59 years, and 13 per 1,000 for those aged 60 years or older. Several of the researchers were employed by Abbott Laboratories.
Epidemiology was the word of the day in a sampling of posters presented at the annual meeting of the American College of Rheumatology. Below are three posters that received a lot of attention at this year's meeting. The report on heart failure risk in rheumatoid arthritis was one of this year's blue ribbon–winning posters.
RA Severity Predicts Heart Failure
The risk for new-onset heart failure in patients with RA is greatest in patients with the most severe disease, Dr. Soko Setoguchi of Brigham and Women's Hospital in Boston and her associates reported. The research involves 8,483 patients whose RA was diagnosed by a rheumatologist and who were enrolled in the CORRONA (Consortium of Rheumatology Researchers of North America) registry. Patients were followed from the time of registry enrollment until Dec. 15, 2006, or death, whichever happened sooner. Patients' mean age was 59 years, 75% were female, 93% were white, 15% were current smokers, and their mean body mass index was 29 kg/m
Women's RA Risk Is Twice Men's
The lifetime risk for RA has remained “remarkably stable” during 1945-1995, according to Cynthia S. Crowson and her associates from the Mayo Clinic in Olmsted, Minn. For men, the lifetime risk is 1.8%; for women, it ranges from 3.4% to 3.7%. This stability occurred despite a gradual decrease in the incidence of RA from 1955 to the mid-1980s. More recently, women are experiencing an increased incidence, whereas that of men remains steady. The investigators used participants in the population-based incident cohort of Olmsted County who fulfilled the 1987 ACR criteria for RA between 1995 and 2005. These findings come from Poisson regression analyses performed to calculate the observed incidence rate in each sex. Calling the lifetime risk “significant” and women's higher lifetime risk “substantial,” the investigators noted an additional worry in their poster: The lifetime risk may be even higher in some subgroups with high-risk genotypes. This research was funded by the National Institutes of Health.
Uveitis Incidence Established in AS
Noninfectious uveitis is more than 20 times more common in patients with ankylosing spondylitis than in the general population, judging from findings presented by Shelagh M. Szabo of Oxford Outcomes in Vancouver, B.C., and colleagues. Using longitudinal physician billing data from Quebec province, the investigators calculated that 7,663 people were diagnosed with AS between 1998 and 2006 (the AS 1 group); another 3,006 people were diagnosed with AS during that time period and were seen for a related visit at least once during the next year (AS 2). The AS 1 group was designed to maximize sensitivity and the AS 2 group to maximize specificity. The AS 1 patients may have had milder disease. The investigators used a 1% random sample of unaffected individuals from Quebec (the population of which was 7.6 million in 2006) as the control group. The crude 10-year incidence of noninfectious uveitis in the AS 1 patients was 368 cases per 10,000 persons; for the AS 2 group, it was 482 cases per 10,000 persons; in the control group, the incidence was 21 cases per 10,000 persons. The standardized incidence ratio (SIR) for uveitis development during the study period was 18.04 for those in AS 1 vs. the controls. The SIR was 23.88 for those in the AS 2 group vs. controls. Age played a significant factor in incidence, with those in the 20- to 39-year-old age group having the largest risk. In the AS 1 group, the uveitis incidence was 53 cases per 1,000 persons in those aged 20-39 years vs. 33 per 1,000 for those aged 40-59 years, and 8 per 1,000 for those aged 60 years or older. In the AS 2 group, the uveitis incidence was 69 per 1,000 persons in those aged 20-39 years vs. 40 per 1,000 persons for those aged 40-59 years, and 13 per 1,000 for those aged 60 years or older. Several of the researchers were employed by Abbott Laboratories.